As demonstrated in prostate cancer, FOXO4 antagonizes RUNX2 activity by physically interacting with and preventing RUNX2 to induce the expression of pro-metastatic genes, such as PIP and PGC [43]. This evidence concerns the gene RUNX2 and prostate carcinoma.